ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1276

Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis

Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: Comorbidity, Disease Activity, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated with higher rates of multimorbidity (i.e., 2 or more chronic conditions). However, little is known about the association between multimorbidity and RA disease activity. We aimed to assess the association between multimorbidity and RA disease flares and remission.

Methods: This retrospective, population-based study included residents of a geographically well-defined area with incident RA in 1999-2014 who fulfilled 1987 ACR criteria for RA. Flare/remission were defined using OMERACT definitions and were manually abstracted from medical records. Flare was defined as a worsening of disease requiring initiation, change, or escalation of therapy or documentation of ‘flare up’ or ‘active’ disease. Remission was defined as an absence of disease activity (e.g., ‘remission’, ‘quiescent’, ‘no activity’) and/or based on ≤1 tender/swollen joints and normal inflammatory markers. Multimorbidity at RA incidence was defined using 55 chronic conditions published previously and was categorized as MM2+ (2 or more comorbidities) or MM5+ (5 or more comorbidities). Binomial mixed models with random effects accounting for multiple visits per patient adjusted for age, sex, RA duration, seropositivity, incidence year, and smoking status were used to assess the association between flare/remission and multimorbidity.

Results: The study included 625 patients with RA (mean age 55.5 years, 70% female, 88% white, 68% seropositive, 47% current/former smokers, 40% obese). Among 7841 visits over a mean follow-up of 8.7 (SD 4.3) years, 2793 were in flare (36%) and 1929 (25%) were in remission. Multimorbidity was modestly associated with flare, but these associations did not reach statistical significance (MM2+: OR 1.22;95% CI: 0.97-1.53, p=0.08; MM5+: OR 1.16; 95%CI 0.94-1.44, p=0.16). Multimorbidity was significantly associated with decreased odds of remission for both MM2+ (OR 0.63; 95%CI 0.46-0.87, p=0.0048) and MM5+ (OR 0.64 [95%CI 0.48-0.87, p=0.0046). Seropositivity was not significantly associated with flare (OR 1.13; 95%CI 0.93-1.40; p=0.21) or remission (OR 1.00; 95%CI 0.75-1.34, p=0.99). Male sex, longer RA duration, and increased age were associated with significantly greater odds of remission and smoking at baseline was associated with significantly decreased odds of remission. RA duration, increased age, and increased year of RA index were associated with significantly lower odds of flare and current smoking with significantly increased odds of flare.

Conclusion: Patients with RA and multimorbidity were less likely to achieve remission. Multimorbidity was a stronger predictor of poor prognosis than seropositivity. These results underscore the importance of considering multimorbidity and not just seropositivity when assessing prognosis for patients with RA. Further research is needed to elucidate the underlying mechanisms of these associations (e.g., whether certain morbidities are associated with poor prognosis, or the impact of patient complexity on adherence or other issues are playing a role).


Disclosures: C. Crowson: None; C. Kodishala: None; T. Gunderson: None; A. Elizabeth: None; V. Kronzer: None; J. Davis: Girihlet, 9, Pfizer, 5, Remission Medical, 9; C. Arment: None; D. Bekele: None; T. Mason: None; L. Peterson: None; K. Wright: None; E. Myasoedova: None.

To cite this abstract in AMA style:

Crowson C, Kodishala C, Gunderson T, Elizabeth A, Kronzer V, Davis J, Arment C, Bekele D, Mason T, Peterson L, Wright K, Myasoedova E. Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/multimorbidity-burden-predicts-lower-likelihood-of-remission-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multimorbidity-burden-predicts-lower-likelihood-of-remission-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology